Articles From: Syntel Reports Second Quarter 2014 Financial Results to Synutra to Announce First Quarter Fiscal 2015 Financial Results


Highlights: Q2 revenue of $228.3M, up 13% from year-ago quarter, 4% sequentially Q2 EPS of $1.41 per diluted share, up 24% from year-ago quarter, 2% sequentially Q2 cash & short term investments of $769.8M Global Headcount of 24,122 on June 30, 2014, up 5% versus prior year TROY, Mich., July 17, 2014 (GLOBE NEWSWIRE) -- Syntel, Inc. (Nasdaq:SYNT) , a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced financial results for the second quarter, ended June 30, 2014.
Sign-up for Syntel Reports Second Quarter 2014 Financial Results investment picks
TROY, Mich., June 24, 2014 (GLOBE NEWSWIRE) -- Syntel, Inc. (Nasdaq:SYNT) , a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced it is a presenting sponsor for the Enactus India National Competition to be held at the Taj Lands' End Hotel in Mumbai, India on July 1 and 2, 2014.
Sign-up for Syntel Sponsors Enactus India Sustainable Entrepreneurship Competition investment picks
2014/7/11
TROY, Mich., July 11, 2014 (GLOBE NEWSWIRE) -- Syntel, Inc., a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, will announce results for the Second Quarter 2014, before the market opens on Thursday, July 17, 2014 Syntel management will conduct a conference call at 10:00 a.m. (EDT) to discuss financial and operating performance for the quarter.
Sign-up for Syntel to Announce Second Quarter 2014 Results on Thursday, July 17, 2014 investment picks
TROY, Mich., July 28, 2014 (GLOBE NEWSWIRE) -- Syntel (Nasdaq:SYNT) , a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies, today announced that the Company will present at the following upcoming investor conference: Needham Interconnect Conference Date: Wednesday, August 6, 2014 Presentation: 12:15PM (Eastern) Location: New York, NY Presenter: Zaineb Bokhari, VP Finance Live webcast available on Syntel's website at http://investor.syntelinc.com About Syntel Syntel (Nasdaq:SYNT) is a global provider of digital transformation, information technology and knowledge process services to Global 2000 companies.
Sign-up for Syntel to Present at Investor Conference investment picks
TROY, Mich., Aug.
Sign-up for Syntel to Present at Investor Conference investment picks
HOUSTON, July 9, 2014 (GLOBE NEWSWIRE) -- Synthesis Energy Systems, Inc. (SES) (Nasdaq:SYMX) today announced that Charles M.
Sign-up for Synthesis Energy Systems Appoints Charles M. Brown to Board of Directors investment picks
HOUSTON, Aug.
Sign-up for Synthesis Energy Systems Strengthens Operations Leadership investment picks
2014/8/28
-- Fujifilm's pAVEway™ Platform Demonstrated >25-fold Improvement in SYN-004 Expression Titers --
Sign-up for Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile investment picks
-- Two of Company's Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C.
Sign-up for Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC investment picks
-- SYN-005 Neutralizing Antibody Combination Protects Against Pertussis in Murine and Non-Human Primate Models --
Sign-up for Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program investment picks
2014/8/5
-- Executed Agreement with Evonik for Formulation Development, Analytical Services andClinical Drug Manufacturing -- --
Sign-up for Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile investment picks
-- Company Expects to File IND to Support Clinical Trials in Mid-2015 --
Sign-up for Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) investment picks
2014/8/14
-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C.
Sign-up for Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights investment picks
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
Sign-up for Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day investment picks
2014/9/11
-- Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT --
Sign-up for Synthetic Biologics to Host Phase II Trimesta™ for Multiple Sclerosis Conference Call investment picks
-- Company Completes Final Preclinical Toxicology Study and Prepares to File Investigational New Drug (IND) in 2H 2014 --
Sign-up for Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections investment picks
2014/8/7
-- Conference Call Scheduled for Thursday, August 14, 2014, at 8:30 am EDT --
Sign-up for Synthetic Biologics to Report Second Quarter 2014 Financial Results investment picks
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
Sign-up for Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day investment picks
2014/7/29
ROCKVILLE, Md.
Sign-up for Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity investment picks
2014/7/21
Company's License from The University of Texas at Austin Covers Development of SYN-005 in Collaboration with Intrexon Corporation ROCKVILLE, Md.
Sign-up for Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference investment picks
-- SYN-005 Program Targeting Pertussis Toxin to be Highlighted in Oral Presentation --
Sign-up for Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC investment picks
-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action --
Sign-up for Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day investment picks
~ 1Q15 Sales Increase 4.6%~ ~Formula Sales Increase 20.8% ~~ Reiterates FY15 Guidance Forecast QINGDAO, China and ROCKVILLE, Md.
Sign-up for Synutra Reports First Quarter Fiscal 2015 Financial Results investment picks
QINGDAO, China and ROCKVILLE, Md.
Sign-up for Synutra to Announce First Quarter Fiscal 2015 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Syntel Reports Second Quarter 2014 Financial Results to Synutra to Announce First Quarter Fiscal 2015 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices